A型肉毒毒素泪腺注射抑制泪液分泌临床应用的研究现状
Current clinical application of lacrimal gland injection of botulinum toxin type A in inhibiting lacrimal secretion
摘要泪腺注射A型肉毒毒素(BTXA)抑制泪液分泌,作为一种新的治疗或缓解流泪或溢泪症状的方法,具有操作简单,疗效确切,可重复治疗,无不可逆的并发症等特点,为许多难治性流泪或溢泪的患者提供一种可选择的治疗方案。本文对BTXA的药理学特征和抑制泪液分泌的机制、泪腺注射的方法及剂量、适应证和禁忌证、临床疗效评价、并发症、目前存在的尚待解决的问题及前景展望等进行综述。
更多相关知识
abstractsLacrimal gland injection of botulinum toxin type A inhibits the secretion of tears. As a new method to treat or alleviate the symptom of tears or epiphora, it has the characteristics of simple operation, definite curative effect, repeatable treatment and no irreversible complications. It provides an optional treatment scheme for many patients with refractory tears or epiphora. This article reviews the pharmacological characteristics of botulinum toxin type A, the mechanism of inhibiting tear secretion, the method and dose of lacrimal gland injection, indications and contraindications, clinical efficacy evaluation, complications, existing problems to be solved and prospects for reference.
More相关知识
- 浏览0
- 被引1
- 下载0

相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



